<DOC>
	<DOC>NCT00608985</DOC>
	<brief_summary>A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.</brief_summary>
	<brief_title>Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Adult subjects (1864 years) with a diagnosis of primary insomnia. History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSMIV) axis I disorder other than primary insomnia. Sleep apnea, or restless legs syndrome. Daytime napping of more than 1 hour per day. Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit. Unwillingness to refrain from drugs, overthecounter or herbal medication having an effect on sleep or behavior.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>sleeplessness</keyword>
	<keyword>orexin receptor antagonist</keyword>
	<keyword>almorexant</keyword>
	<keyword>insomnia</keyword>
</DOC>